Biogen Advances Alzheimer’s Drug to Late-Stage Trial Despite Mixed Mid-Stage Data
Biogen intends to proceed with late-stage testing for an experimental Alzheimer's disease drug, despite mixed results from its mid-stage trial.
Markets, economy, and policy news for investors.
Investor topic hub
Macro stories that shape growth, inflation, labor markets, household spending, public budgets, and investor expectations.